Multiple sclerosis trials recruiting in Georgia

All Multiple sclerosis trials nationally

Cities in Georgia

Recruiting trials in Georgia

• A Study Evaluating the Presence and Concentration of BRIUMVI™ (Ublituximab) in Breast Milk
  NCT06143514 · Phase: Not specified · Ages: 18 Years and older · Sex: Female · Georgia: Smyrna
• A Study Evaluating the Real World Experience of Participants Treated With BRIUMVI® (Ublituximab-xiiy) for Relapsing Multiple Sclerosis (RMS)
  NCT06433752 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female) · Georgia: Atlanta, Savannah, Smyrna
• A Study of Ocrelizumab Administered Subcutaneously in Participants With Multiple Sclerosis Who Switch From an Approved Anti-CD20 Therapy
  NCT07609719 · Phase: Phase 4 · Ages: 18 Years to 65 Years · Sex: All (male and female) · Georgia: Atlanta
• A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis
  NCT07225504 · Phase: Phase 3 · Ages: 18 Years to 65 Years · Sex: All (male and female) · Georgia: Smyrna
• Effects of Ublituximab on Motor Functions in Multiple Sclerosis
  NCT06629428 · Phase: Early Phase 1 · Ages: 18 Years to 55 Years · Sex: All (male and female) · Georgia: Atlanta
• Incremental Vestibulo-ocular Reflex Adaptation as a Novel Treatment for Dizziness in People With Multiple Sclerosis
  NCT06495138 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years to 89 Years · Sex: All (male and female) · Georgia: Atlanta
• Motor Learning of Fall Resistant Skills Through Slip and Trip Exposure in Multiple Sclerosis
  NCT06919900 · Phase: Not applicable (e.g. observational or device study) · Ages: 45 Years to 89 Years · Sex: All (male and female) · Georgia: Atlanta
• Non-inferiority Study of Frexalimab Subcutaneous Administration Compared to Intravenous Administration in Adult Participants With Multiple Sclerosis
  NCT07325292 · Phase: Phase 3 · Ages: 18 Years to 60 Years · Sex: All (male and female) · Georgia: Smyrna
• RE104 Safety and Efficacy Study in Adjustment Disorder in Cancer and Other Medical Illnesses
  NCT07002034 · Phase: Phase 2 · Ages: 18 Years to 80 Years · Sex: All (male and female) · Georgia: Atlanta
• Study of COYA 302 for the Treatment of ALS
  NCT07161999 · Phase: Phase 2, Phase 3 · Ages: 18 Years to 80 Years · Sex: All (male and female) · Georgia: Atlanta
• Study to Evaluate Safety, Efficacy and Pharmacokinetics (PK) of a Modified Regimen of Ublituximab
  NCT05877963 · Phase: Phase 3 · Ages: 18 Years to 65 Years · Sex: All (male and female) · Georgia: Atlanta, Savannah
• Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO
  NCT03816345 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · Georgia: Atlanta
• The SetPoint System as a Pro-Remyelination Therapy for Relapsing-Remitting Multiple Sclerosis: A Pilot Study
  NCT06796504 · Phase: Not applicable (e.g. observational or device study) · Ages: 22 Years to 60 Years · Sex: All (male and female) · Georgia: Atlanta